BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 9990469)

  • 1. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
    Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
    Manavathu EK; Abraham OC; Chandrasekar PH
    Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant
    Dellière S; Verdurme L; Bigot J; Dannaoui E; Senghor Y; Botterel F; Fekkar A; Bougnoux ME; Hennequin C; Guitard J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
    Oakley KL; Moore CB; Denning DW
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2726-30. PubMed ID: 9756785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD; Kiraz N
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL; Moore CB; Denning DW
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp.
    Gomez-Lopez A; Garcia-Effron G; Mellado E; Monzon A; Rodriguez-Tudela JL; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3085-8. PubMed ID: 14506013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
    Krishnan-Natesan S; Wu W; Chandrasekar PH
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.
    Pfaller MA; Duncanson F; Messer SA; Moet GJ; Jones RN; Castanheira M
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5155-8. PubMed ID: 21844312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp.
    Moore CB; Law D; Denning DW
    J Antimicrob Chemother; 1993 Dec; 32(6):831-6. PubMed ID: 8144422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of environmental versus clinical strains of pathogenic Aspergillus.
    Araujo R; Pina-Vaz C; Rodrigues AG
    Int J Antimicrob Agents; 2007 Jan; 29(1):108-11. PubMed ID: 17189101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.